RxDoctor Payments Data

Randall Scott

Psychiatry · Lynchburg, VANPI 1528069267

Payments from drug & device makers

$1,912in general payments, 2019–2025

Across 111 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$548
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$326
  • Neurocrine Biosciences, Inc.$244
  • Otsuka America Pharmaceutical, Inc.$176
  • Vanda Pharmaceuticals Inc.$139
  • Takeda Pharmaceuticals U.S.A., Inc.$136
  • plus $342 from 8 others

What the payments were for

  • Food & beverage$1,86598%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,912 in reported general payments places this provider in the 80th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$56,476
Medicare patients
140
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine29$194,728
IngrezzaValbenazine Tosylate21$175,916
VraylarCariprazine Hcl30$53,357
FanaptIloperidone12$27,286
RexultiBrexpiprazole18$25,822
BelsomraSuvorexant40$17,520
Ambien CrZolpidem Tartrate12$8,773
Lurasidone Hcl20$6,695
Aripiprazole161$5,400
Bupropion XlBupropion Hcl230$5,357
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine53$3,944
Trazodone Hcl271$3,809
Duloxetine Hcl162$3,516
Quetiapine Fumarate193$3,105
Chlorpromazine Hcl25$2,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Loxapine$47$196,63844 claims
Neurocrine Biosciences, Inc.Ingrezza$244$175,91621 claims
Vanda Pharmaceuticals Inc.Fanapt$139$27,28612 claims
Otsuka America Pharmaceutical, Inc.Rexulti$176$25,82218 claims
MerckBelsomra$15$17,52040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →